Barclays analyst Eliana Merle downgraded Regenxbio Inc. (NASDAQ: RGNX) from Overweight to Equalweight with a price target of $12.00.The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE